---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-007824"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:47:07.821233+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alector Q1 rev $24.5M, net loss $44.6M; latozinemab shows 54% disease progression delay in FTD-C9orf72

## Summary
- Collaboration revenue $24.5M (vs $4.1M YoY) from GSK agreement; net loss $44.6M ($0.54/share) improved from $52.2M loss.
- Cash, cash equivalents, and marketable securities $868.6M; sufficient to fund operations into mid-2024.
- INFRONT-2 Phase 2: latozinemab in FTD-C9orf72 showed ~54% annual delay in disease progression vs matched control.
- AL101 Phase 1 enrollment completed; data expected H2 2022. AL044 Phase 1 to initiate H2 2022.
- Gary Romano, M.D., Ph.D., joins as CMO on May 23, 2022; Marc Grasso, M.D., joined as CFO.

## SEC filing metadata
- accession: 0000950170-22-007824
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017022007824/0000950170-22-007824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017022007824/alec-20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-007824
- JSON: https://secwatch.observer/filing/0000950170-22-007824.json
- Plain text: https://secwatch.observer/filing/0000950170-22-007824.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.